Saccharomyces cerevisiae prevents postoperative recurrence of Crohn's disease modeled by ileocecal resection in HLA-B27 transgenic rats

Postoperative recurrence (POR) after ileocecal resection (ICR) affects most Crohn's disease patients within 3-5 years after surgery. Adherent-invasive (AIEC) typified by the LF82 strain are pathobionts that are frequently detected in POR of Crohn's disease and have a potential role in the...

Full description

Saved in:
Bibliographic Details
Published in:World journal of gastroenterology : WJG 2023-02, Vol.29 (5), p.851-866
Main Authors: Valibouze, Caroline, Speca, Silvia, Dubuquoy, Caroline, Mourey, Florian, M'Ba, Lena, Schneider, Lucil, Titecat, Marie, Foligné, Benoît, Genin, Michaël, Neut, Christel, Zerbib, Philippe, Desreumaux, Pierre
Format: Article
Language:English
Subjects:
Animals
Bacterial Adhesion
Basic Study
Crohn Disease - pathology
Escherichia coli
Escherichia coli Infections
HLA-B27 Antigen
Intestinal Mucosa - pathology
Life Sciences
Rats
Rats, Inbred F344
Rats, Transgenic
Saccharomyces cerevisiae
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Postoperative recurrence (POR) after ileocecal resection (ICR) affects most Crohn's disease patients within 3-5 years after surgery. Adherent-invasive (AIEC) typified by the LF82 strain are pathobionts that are frequently detected in POR of Crohn's disease and have a potential role in the early stages of the disease pathogenesis. CNCM I-3856 is a probiotic yeast reported to inhibit AIEC adhesion to intestinal epithelial cells and to favor their elimination from the gut. To evaluate the efficacy of CNCM I-3856 in preventing POR induced by LF82 in an HLA-B27 transgenic (TgB27) rat model. Sixty-four rats [strain F344, 38 TgB27, 26 control non-Tg (nTg)] underwent an ICR at the 12 wk (W12) of life and were sacrificed at the 18 wk (W18) of life. TgB27 rats were challenged daily with oral administration of LF82 (10 colony forming units (CFUs)/day (d), = 8), PBS ( = 5), CNCM I-3856 (10 CFUs/d, = 7) or a combination of LF82 and CNCM I-3856 ( = 18). nTg rats receiving LF82 ( = 5), PBS ( = 5), CNCM I-3856 ( = 7) or CNCM I-3856 and LF82 ( = 9) under the same conditions were used as controls. POR was analyzed using macroscopic (from 0 to 4) and histologic (from 0 to 6) scores. Luminal LF82 quantifications were performed weekly for each animal. Adherent LF82 and inflammatory/regulatory cytokines were quantified in biopsies at W12 and W18. Data are expressed as the median with the interquartile range. nTg animals did not develop POR. A total of 7/8 (87%) of the TgB27 rats receiving LF82 alone had POR (macroscopic score ≥ 2), which was significantly prevented by CNCM I-3856 administration [6/18 (33%) TgB27 rats, = 0.01]. Macroscopic lesions were located 2 cm above the anastomosis in the TgB27 rats receiving LF82 alone and consisted of ulcerations with a score of 3.5 (2 - 4). Seven out of 18 TgB27 rats (39%) receiving CNCM I-3856 and LF82 had no macroscopic lesions. Compared to untreated TgB27 animals receiving LF82 alone, coadministration of CNCM I-3856 and LF82 significantly reduced the macroscopic [3.5 (2 - 4) 1 (0 - 3), = 0.002] and histological lesions by more than 50% [4.5 (3.3 - 5.8) 2 (1.3 - 3), = 0.003]. The levels of adherent LF82 were correlated with anastomotic macroscopic scores in TgB27 rats ( = 0.49, = 0.006), with a higher risk of POR in animals having high levels of luminal LF82 (71.4% 25%, = 0.02). Administration of CNCM I-3856 significantly reduced the levels of luminal and adherent LF82, increased the production of interleukin (IL)-10 and decreased the
ISSN:1007-9327
2219-2840
DOI:10.3748/wjg.v29.i5.851